Clinical experience with exenatide in a routine secondary care diabetes clinic

Abstract Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA1c were 114.9 ± 20.6 kg, 10.3 ± 2.1% at initiation; 108.0 ± 15.3 kg ( p < 0.0001), 9.0 ± 2.1% ( p < 0.001) at 3 months; 109.2 ± 18.2 kg ( p < 0.0...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Primary care diabetes 2010-04, Vol.4 (1), p.57-60
Hauptverfasser:	Natarajan, B, Edavalath, M, Davies, J, Jenkins, L, Marshall-Richards, N, Evans, D, Price, D.E, Bain, S.C, Stephens, J.W
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose - drug effects Blood Glucose - metabolism BMI Body Mass Index Body Weight Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Drug Therapy, Combination Endocrinology & Metabolism Exenatide Glycated Hemoglobin A - metabolism HBA 1c Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Internal Medicine Peptides - therapeutic use Routine Practice Sulfonylurea Compounds - therapeutic use Treatment Outcome Type 2 diabetes mellitus Venoms - therapeutic use Weight Weight Loss
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Exenatide use in type 2 diabetes is limited in routine clinical practice. We examined a cross-section of 90 patients. Mean weight and HBA1c were 114.9 ± 20.6 kg, 10.3 ± 2.1% at initiation; 108.0 ± 15.3 kg ( p < 0.0001), 9.0 ± 2.1% ( p < 0.001) at 3 months; 109.2 ± 18.2 kg ( p < 0.0001), 9.5 ± 2.3% ( p = 0.08) at 6 months. Exenatide appears effective in reducing HBA1c and weight.
ISSN:	1751-9918 1878-0210
DOI:	10.1016/j.pcd.2009.11.001